By Elias Schisgall

Shares of the Oncology Institute rose after the company raised its outlook following a quarter of revenue growth.

The stock was up 15% in after-hours trading, at $3.57. Ahead of Thursday's close, the stock had risen nearly tenfold year-to-date.

The company, which focuses on cancer care, posted a third-quarter loss of $16.5 million, or 14 cents a share, compared with a loss of $16.1 million, or 18 events a share, a year earlier.

Analysts polled by FactSet were expecting a loss of 11 cents a share.

Operating revenue rose to $136.6 million, compared with $99.9 million a year earlier. The increase was fueled by a rise in dispensary and patient services revenue, while partially offset by a dip in revenue from clinical trials.

The company upped its full-year guidance to between $495 million and $505 million, from prior guidance of between $460 million and $480 million. Analysts polled by FactSet were expecting $474.1 million.

Chief Executive Daniel Virnich said Oncology Institute was able to raise its outlook based on growth in its pharmacy business and a strong performance in Florida, as well as its implementation of artificial intelilgence in operations and the patient experience.

"As a leader in oncology value-based care, it is important for us to not only raise the quality of care but also lower that cost of care," Virnich said. "We believe we are well-positioned to achieve this goal, while simultaneously driving durable and sustainable growth."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

November 13, 2025 18:03 ET (23:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.